Antibodies

18 June 2016

Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae using Monoclonal Antibody Technology

18 June 2016

Medivation’s Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG)

17 June 2016

Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma

16 June 2016

Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer

15 June 2016

Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101

15 June 2016

EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011

13 June 2016

True North’s Lead Product Candidate, TNT009, Demonstrates High Response Rates and Rapid Onset of Action in Interim Clinical Data in Patients with Cold Agglutinin Disease (CAD)

13 June 2016

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

13 June 2016

Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

11 June 2016

Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru

10 June 2016

Coherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept

10 June 2016

Daratumumab Significantly Extended Progression-Free Survival in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

10 June 2016

Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH

10 June 2016

New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial

10 June 2016

BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

10 June 2016

Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA™ (bezlotoxumab), an Investigational Agent for Prevention of Clostridium difficile Infection Recurrence

10 June 2016

Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases

10 June 2016

Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers

10 June 2016

UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis

9 June 2016

Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society

9 June 2016

Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody

9 June 2016

Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients’ Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine

9 June 2016

Studies Demonstrate Lilly’s Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine

9 June 2016

New data demonstrates Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products

8 June 2016

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH

8 June 2016

New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease

8 June 2016

Samsung Bioepis Announces New Data on Three Anti-TNF-α Biosimilar Molecules at the Annual European Congress on Rheumatology (EULAR 2016)

8 June 2016

Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)

8 June 2016

Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016

8 June 2016

Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: Bispecific Antibodies

TROP-2-Targeted Immunotherapy Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Ustekinumab (Stelara) Biosimilars Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Adalimumab (Humira) Biosimilars Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins